A Prospective, Multicenter, Randomized, Blinded, Sham-controlled, Feasibility Study of Renal Denervation in Patients With Chronic Heart Failure

Inclusion Criteria

• •Patient with CHF diagnosed for at least 3 months prior to consent
• •6-min walk distance ≤350 m
• •NYHA Class II-III symptoms of CHF
• •Systolic left ventricular dysfunction as assessed by echocardiogram with left ventricular ejection fraction \<45%
• •eGFR calculated (CKD-EPI) \>30 ml/min/1.73 m2
• •NT-pro-BNP \>450 pg/ml, \>900 pg/ml for patients with atrial fibrillation
• •Optimal medical drug therapy according to current guidelines for CHF management. This medication may include loop diuretics, ACEi/ARBs, ARNI, SGLT-2 inhibitors, aldosterone antagonists, and beta-blockers, unless intolerance to any of the above is documented. Treatment for HF must be stable (including drug and dose) for 4 weeks prior to randomization, except diuretics (2 weeks stable)
• •Appropriate use of medical devices such as an implantable cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) consistent with prevailing local or international guidelines, and if a device is required, it must have been implanted for at least 3 months prior to consent for CRT and 1 month prior to consent for ICD
• •Age ≥18 years and ≤80 years